Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS

Glucose Transporter Type 1 Deficiency Syndrome

Juan Pascual – Glut1 Deficiency Syndrome Juan Pascual – Glucose Transporter Type 1 Deficiency Syndrome

Ketonemia Through Menstrual Cycle Brain Metabolism Observed at 7 Tesla Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) Treatment Development of Triheptanoin (G1D) Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D Evaluation of Keyo in Children With Epilepsy The Glucose Transporter Type I Deficiency (G1D) Registry Evaluation of Ketoflo Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome Evaluation of Krio in Children and Adults With Epilepsy Post Study Continuation of C7 for G1D Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) Sodium Lactate Infusion in GLUT1DS Patients Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)